Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2
|
作者：
Packer, Milton [1 ,2 ]
Cleland, John G. F. [3 ]
Bauersachs, Johann [4 ]
机构：
[1] Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期
关键词：
Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;
D O I：
10.1093/eurheartj/ehae300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
引用
收藏
页码：2186 / 2196
页数：11
相关论文
共 50 条
  • [1] SGLT2 inhibitors in heart failure with reduced ejection fraction
    Uday Sankar Das
    Aritra Paul
    Suvro Banerjee
    The Egyptian Heart Journal, 73
  • [2] SGLT2 inhibitors in heart failure with reduced ejection fraction
    Das, Uday Sankar
    Paul, Aritra
    Banerjee, Suvro
    EGYPTIAN HEART JOURNAL, 2021, 73 (01):
  • [3] SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi, Emanuel
    Fadini, Gian Paolo
    Diemberger, Igor
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (05) : 647 - 650
  • [4] Cardiac remodeling with SGLT2 inhibitors in heart failure with reduced ejection fraction
    Romeo, Francisco J.
    Del Buono, Marco G.
    Aguilar-gallardo, Jose S.
    Lorente-ros, Marta
    Damonte, Juan I.
    Chiabrando, Juan G.
    Dixon, Dave L.
    Biondi-zoccai, Giuseppe
    Abbate, Antonio
    Carbone, Salvatore
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2024, 72 (01) : 95 - 97
  • [5] SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
    Jhund, Pardeep S.
    HEART FAILURE CLINICS, 2022, 18 (04) : 579 - 586
  • [6] Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction
    Li, Song
    Levy, Wayne C.
    JACC-HEART FAILURE, 2022, 10 (05) : 319 - 320
  • [7] Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
    Pabel, Steffen
    Hamdani, Nazha
    Singh, Jagdeep
    Sossalla, Samuel
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [8] SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
    Lenahan, Christy McDonald
    Harrington, Deedra
    Stueben, Frances
    NURSE PRACTITIONER, 2021, 46 (07): : 30 - 37
  • [9] External validation of landmark SGLT2 inhibitors trials in heart failure with reduced ejection fraction
    Simard, L. Louis
    Cote, S.
    Joncas, S. X.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 25 - 25
  • [10] Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    Lisenby, Katelin M.
    Osmonson, Alyssa
    PHARMACOTHERAPY, 2021, 41 (06): : 526 - 536
12345